4 D Molecular Therapeutics, Inc. - Understand $fdmt stock

$FDMT Market Cap: $330.1 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$20.76M

TTM

Gross Margin

Net Earnings

-$212.0M

TTM

Current Assets

$510.8M

Q3 2024

Current Liabilities

$29.47M

Q3 2024

Current Ratio

1733.44%

Q3 2024

Total Assets

$604.0M

Q3 2024

Total Liabilities

$51.08M

Q3 2024

Book Value

$552.9M

Q3 2024

Cash

$187.5M

Q3 2024

P/E

-1.557

Nov 29, 2024 EST

Free Cash Flow

-$116.8M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$20.72M	$3.129M	$18.04M	$13.61M	$6.986M	$14.13M	$5.790M
YoY Change	562.29%	-82.65%	32.52%	94.85%	-50.56%	144.04%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$20.72M	$3.129M	$18.04M	$13.61M	$6.986M	$14.13M	$5.790M
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017
Selling, General & Admin	$36.49M	$32.91M	$28.01M	$17.24M	$13.90M	$6.170M	$3.490M
YoY Change	10.9%	17.48%	62.48%	24.03%	125.28%	76.79%
% of Gross Profit
Research & Development	$97.10M	$80.25M	$61.36M	$53.04M	$38.72M	$18.36M	$13.57M
YoY Change	20.99%	30.79%	15.69%	36.99%	110.88%	35.3%
% of Gross Profit
Depreciation & Amortization	$4.400M	$2.400M	$1.500M	$1.400M	$1.000M	$700.0K	$630.0K
YoY Change	83.33%	60.0%	7.14%	40.0%	42.86%	11.11%
% of Gross Profit
Operating Expenses	$133.6M	$113.2M	$89.37M	$70.28M	$57.75M	$24.53M	$17.06M
YoY Change	18.05%	26.62%	27.17%	21.69%	135.43%	43.79%
Operating Profit	-$112.9M	-$110.0M	-$71.33M	-$56.66M	-$50.76M
YoY Change	2.58%	54.25%	25.89%	11.62%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017
Interest Expense	$12.21M	$2.573M	$137.0K	$150.0K	$1.500M	$850.0K	$90.00K
YoY Change	374.58%	1778.1%	-8.67%	-90.0%	76.47%	844.44%
% of Operating Profit
Other Income/Expense, Net	$12.03M	$2.538M	$16.00K	-$29.00K	$1.458M	$0.00	-$40.00K
YoY Change	374.0%	15762.5%	-155.17%	-101.99%		-100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017
Pretax Income	-$100.8M	-$107.5M	-$71.32M	-$56.69M	-$49.31M	-$9.550M	-$11.22M
YoY Change	-6.19%	50.73%	25.8%	14.97%	416.34%	-14.88%
Income Tax	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$100.8M	-$107.5M	-$71.32M	-$56.69M	-$49.31M	-$9.550M	-$11.22M
YoY Change	-6.19%	50.73%	25.8%	14.98%	416.29%	-14.88%
Net Earnings / Revenue	-486.59%	-3435.41%	-395.37%	-416.49%	-705.78%	-67.59%	-193.78%
Basic Earnings Per Share	-$2.58	-$3.32	-$2.57
Diluted Earnings Per Share	-$2.58	-$3.32	-$2.572M	-$8.816M	-$9.375M	-$1.816M	-$2.133M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017
Cash & Short-Term Investments	$288.2M	$213.6M	$247.8M	$276.7M	$49.70M	$91.80M	$23.90M
YoY Change	34.97%	-13.81%	-10.45%	456.74%	-45.86%	284.1%
Cash & Equivalents	$249.1M	$52.35M	$153.0M	$276.7M	$49.70M	$91.80M	$23.90M
Short-Term Investments	$39.12M	$161.2M	$94.78M
Other Short-Term Assets	$8.356M	$6.957M	$8.456M	$4.400M	$1.900M	$1.200M	$300.0K
YoY Change	20.11%	-17.73%	92.18%	131.58%	58.33%	300.0%
Inventory
Prepaid Expenses
Receivables		$0.00	$47.00K	$1.500M	$1.000M	$1.100M	$300.0K
Other Receivables		$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$296.6M	$220.5M	$256.3M	$282.7M	$52.50M	$94.10M	$24.50M
YoY Change	34.5%	-13.96%	-9.35%	438.48%	-44.21%	284.08%
Property, Plant & Equipment	$31.67M	$35.35M	$28.95M	$5.100M	$5.000M	$2.500M	$2.700M
YoY Change	-10.42%	22.08%	467.71%	2.0%	100.0%	-7.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$10.95M	$4.908M	$67.65M
YoY Change	123.19%	-92.75%
Other Assets	$684.0K	$1.080M	$602.0K	$600.0K	$700.0K	$400.0K	$100.0K
YoY Change	-36.67%	79.4%	0.33%	-14.29%	75.0%	300.0%
Total Long-Term Assets	$43.30M	$41.34M	$97.21M	$5.600M	$5.700M	$2.900M	$2.800M
YoY Change	4.76%	-57.48%	1635.84%	-1.75%	96.55%	3.57%
Total Assets	$339.9M	$261.8M	$353.5M	$288.3M	$58.20M	$97.00M	$27.30M
YoY Change
Accounts Payable	$3.515M	$3.322M	$4.764M	$1.800M	$1.700M	$1.000M	$500.0K
YoY Change	5.81%	-30.27%	164.67%	5.88%	70.0%	100.0%
Accrued Expenses	$13.58M	$10.08M	$7.402M	$4.800M	$3.100M	$1.600M	$1.000M
YoY Change	34.73%	36.19%	54.21%	54.84%	93.75%	60.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.95M	$15.73M	$16.34M	$16.70M	$13.00M	$8.100M	$5.900M
YoY Change	20.47%	-3.72%	-2.17%	28.46%	60.49%	37.29%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$13.11M	$14.78M	$18.04M	$15.20M	$15.30M	$13.50M	$22.50M
YoY Change	-11.28%	-18.09%	18.7%	-0.65%	13.33%	-40.0%
Total Long-Term Liabilities	$13.11M	$14.78M	$18.04M	$15.20M	$15.30M	$13.50M	$22.50M
YoY Change	-11.28%	-18.09%	18.7%	-0.65%	13.33%	-40.0%
Total Liabilities	$32.06M	$30.51M	$34.38M	$31.90M	$28.20M	$21.60M	$28.40M
YoY Change	5.09%	-11.26%	7.77%	13.12%	30.56%	-23.94%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	39.13M	32.35M	27.73M
Diluted Shares Outstanding	39.13M	32.35M	27.73M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $330.07 Million

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. The company is headquartered in Emeryville, California and currently employs 147 full-time employees. The company went IPO on 2020-12-11. The firm has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Industry: Biological Products, (No Diagnostic Substances) Peers: Aadi Bioscience, Inc. AVEO PHARMACEUTICALS, INC. Vaxart, Inc. Outlook Therapeutics, Inc. Poseida Therapeutics, Inc. Summit Therapeutics Inc. Vaxxinity, Inc.